Skip to main content

Advertisement

Table 4 Subgroup analysis for progression-free survival, overall survival and objective response rate

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Group PFS OS ORR
No.of studies HR (95% CI) P I2 (%) No.of studies HR (95% CI) P I2 (%) No.of studies RR (95% CI) P I2 (%)
Total 3 1.06 [0.98, 1.15] 0.13 0 8 0.92 [0.79–1.07] 0.29 61 8 1.03 [0.93, 1.13] 0.58 48
Nation
 USA 1 1.05 [0.90, 1.22] 0.53 NA 4 0.86 [0.77, 0.95] 0.004 28 2 1.24 [1.03, 1.51] 0.03 0
 Canada 1 1.08 [0.98, 1.19] 0.12 NA 2 1.25 [0.78, 1.98] 0.35 75 1 0.91 [0.81, 1.04] 0.16 NA
 Korea 1 0.91 [0.64, 1.30] 0.62 NA 1 0.70 [0.49, 0.99] 0.04 NA 1 1.57 [0.98, 2.52] 0.06 NA
 Italy NA NA NA NA 1 0.94 [0.38, 2.32] 0.89 NA 2 1.28 [0.90, 1.82] 0.17 NA
 UK NA NA NA NA NA NA NA NA 1 1.05 [0.35, 3.16] 0.93 NA
 France NA NA NA NA NA NA NA NA 1 0.89 [0.48, 1.63] 0.70 NA
The number of pazopanib
 >100 2 1.07 [0.99, 1.16] 0.1 0 3 0.93 [0.81, 1.06] 0.26 60 2 1.05 [0.78, 1.42] 0.73 85
 <100 1 0.91 [0.64, 1.30] 0.62 NA 5 0.95 [0.65, 1.38] 0.77 69 6 1.25 [0.96, 1.62] 0.09 0
classification a
 Poor risk 1 0.91 [0.64, 1.30] 0.62 NA 2 0.90 [0.56, 1.44] 0.66 78 1 1.57 [0.98, 2.52] 0.06 NA
 Intermediate risk NA NA NA NA 2 1.36 [0.73, 2.52] 0.33 73 NA NA NA NA
 Mixed group 2 1.07 [0.99, 1.16] 0.1 0 7 0.95 [0.82, 1.11] 0.54 61 7 1.01 [0.91, 1.11] 0.85 43
Study design
 RS 2 1.07 [0.97, 1.17] 0.17 0 7 0.93 [0.77, 1.12] 0.44 67 5 1.17 [0.85, 1.61] 0.33 58
 RCT 1 1.05 [0.90, 1.22] 0.53 NA 1 0.91 [0.76, 1.08] 0.29 NA 3 1.19 [1.00, 1.43] 0.05 0
  1. Abbreviations: PFS: progression-free survival, OS: overall survival, ORR: objective response rate, HR, hazard ratio, RR: relative risk, RS: retrospective study, RCT: randomized controlled trial, NA: not available
  2. a Patients were classified according to the International mRCC Database Consortium (IMDC) risk group